drugset / Trial / NCT01696643
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
Timeline
- Start
- 2012-10-12
- Primary completion
- 2014-07-21
- Completion
- 2014-07-21
Outcome
Outcome not reported
Stopped: “A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bevenopran | Small molecule | 0.25 mg | Oral |